Boditech Med Inc. (Boditech) and SphingoTec GmbH (SphingoTec) announced they have entered into a non-exclusive royalty-bearing license agreement. Under the terms of this agreement, Boditech has obtained the rights to develop and commercialize clinical tests for the kidney function biomarker penKid on its renowned AFIAS and ichroma Point of Care platforms. Through this partnership, Boditech and SphingoTec will make the biomarker penKid available on Boditech's worldwide installed base with the goal of improving the management of patients suffering from acute kidney injury (AKI). AKI affects one in five hospitalized patients .

The critical state is currently diagnosed by standard-of-care biomarkers when 50% of the kidney function is already lost . PenKid addresses these pitfalls, offering an earlier and more precise determination of kidney function in acute and critical care settings.